Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Aug;3(8):843-5.
doi: 10.1158/2159-8290.CD-13-0296.

Energizing the search to target LKB1-mutant tumors

Adam I Marcus  1 , Fadlo R Khuri
Affiliations
Comment

Energizing the search to target LKB1-mutant tumors

Adam I Marcus et al. Cancer Discov. 2013 Aug.

Abstract

LKB1 is the third most frequently mutated gene in non-small cell lung cancer and serves as a master regulator of cell metabolism and polarity across a variety of model organisms. Recent studies are beginning to identify therapeutics that exploit defects associated with LKB1 loss. The work presented here by Liu and colleagues shows that deoxythymidylate kinase is a new potential target in LKB1-deficient tumors and highlights the possibility of a new therapeutic option for this subset of patients with cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagram showing some of the pathway defects associated with a Kras, Lkb1 mutation followed by potential targets and therapies. Note, to our knowledge a DTYMK inhibitor has not been developed yet against LKB1 deficient cells or tumors.
See this image and copyright information in PMC

Comment on

  • Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.
    Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Liu Y, et al. Cancer Discov. 2013 Aug;3(8):870-9. doi: 10.1158/2159-8290.CD-13-0015. Epub 2013 May 28. Cancer Discov. 2013. PMID: 23715154 Free PMC article.

References

    1. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998;391:184–7. - PubMed
    1. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002;62:3659–62. - PubMed
    1. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007;26:5911–8. - PMC - PubMed
    1. Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, et al. Somatic LKB1 mutations promote cervical cancer progression. PloS one. 2009;4:e5137. - PMC - PubMed
    1. Guldberg P, thor Straten P, Ahrenkiel V, Seremet T, Kirkin AF, Zeuthen J. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene. 1999;18:1777–80. - PubMed

MeSH terms

Substances